A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

NCT06375993 · clinicaltrials.gov ↗

PHASE1

Phase

ENROLLING_BY_INVITATION

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis
Autoimmune Diseases
Systemic Sclerosis (SSc)
Systemic Lupus Erythematosus (SLE)
ANCA-Associated Vasculitis (AAV)
Idiopathic Inflammatory Myopathies
Stiff Person Syndrome

Interventions

DRUG: ADI-001
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Adicet Therapeutics